Abogen Biosciences is a clinical-stage biotechnology company developing mRNA drugs and vaccines for infectious diseases, oncology and autoimmune conditions.
Abogen Biosciences, founded in 2019 and headquartered in Suzhou, Jiangsu, China, has built a fully integrated mRNA platform covering protein engineering, sequence design, proprietary LNP delivery with Phase 3-validated ionizable lipids, formulation and GMP manufacturing. Its pipeline includes the ARCoV COVID-19 vaccine (first mRNA candidate to enter clinical trials in China), lyophilized RSV and shingles (VZV) vaccines, and oncology candidates such as ABO2203 CD3xCD19 bispecific T-cell engager and ABO2102 KRAS vaccine.
The company has raised over $1B including large Series C and C+ rounds with participation from Qiming Venture Partners and others, and maintains partnerships such as with Walvax for ARCoV. It focuses on thermostable formulations and in vivo expression technologies for vaccines and therapeutics.
